Delivering the latest trends shaping science, biotech, and healthcare — showcasing work that drives revenue, reputation, and investment for compelling brands — and offering an inside look at the award-winning culture behind it all.
Doubts about the future of CRISPR have pervaded the conversation surrounding gene editing. Join HDMZ’s SVP of Public Relations, John Kang, as he addresses these concerns — and explains why there’s still reason to be hopeful.
In exciting news from the frontiers of gene editing, Beam Therapeutics has reported promising Phase 1/2 data from its latest CRISPR clinical trial. The company utilized in vivo base editing to correct a mutation causing alpha-1 antitrypsin deficiency (AATD), a debilitating lung condition, in several patients. Although early, Beam’s initial data marks a potential breakthrough as the first successful use of CRISPR to fix a disease-causing mutation, offering hope for tens of thousands affected.
.png?upscale=true&width=1200&upscale=true&name=image%20(15).png)
.png?upscale=true&width=1080&upscale=true&name=image%20(11).png)
.png?upscale=true&width=1080&upscale=true&name=image%20(12).png)
